Pradaxa Safety as Expected in New FDA Study

The U.S. Food and Drug Administration released the results of a study on the safety and efficacy of dabigatran (Pradaxa) in 134,000 Medicare recipients with nonvalvular atrial fibrillation. New users of dabigatran — versus warfarin (blood thinner) — had reduced risks of ischemic stroke, intracranial hemorrhage and death. The risk of major gastrointestinal (GI) bleeding was higher with dabigatran, but there was no difference in the risk of heart attack. Via Medpage. Posted May 13, 2014.

–Alanna McCatty


Alanna McCatty

Alanna McCatty

Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.


Did you find this article helpful?


Latest News

News Scan: Breast Cancer, THC Overdose, Carpal Tunnel Syndrome, Junk Food

News Scan: Breast Cancer, THC Overdose, Carpal Tunnel Syndrome, Junk Food

Breast cancer tops the list this week with two research studies concluding worse news than expected. For those who continue to claim that no one overdoses on cannabis or THC, see the story below. Never underestimate how much people will underestimate the power of “herbs” to harm. Carpal tunnel brought…